SVRA Stock Forecast: Savara, Inc. Price Predictions for 2026-2027
The 9 Wall Street analysts covering Savara, Inc. hold a median 12-month price target of $11 — +147.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Savara, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (75): The share price has been relatively steady.
Quality (23): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SVRA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SVRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +147.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | HC Wainwright & Co. | Assumes | Buy | $10 |
| 7 Oct 2026 | JP Morgan | Initiates | Overweight | $12 |
| 23 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $10 |
| 18 Dec 2025 | Wells Fargo | Maintains | Overweight | $7.00 → $9.00 |
| 14 Nov 2025 | Oppenheimer | Maintains | Outperform | — |
| 13 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 23 Oct 2025 | JMP Securities | Maintains | Market Outperform | — |
| 9 Sept 2025 | Guggenheim | Maintains | Buy | — |
| 8 Sept 2025 | Oppenheimer | Maintains | Outperform | — |
| 3 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Aug 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
| 15 Aug 2025 | Oppenheimer | Maintains | Outperform | — |
| 1 June 2025 | Oppenheimer | Maintains | Outperform | — |
| 29 May 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 28 May 2025 | Evercore ISI Group | Maintains | In-Line | — |
| 28 May 2025 | Guggenheim | Maintains | Buy | — |
| 28 May 2025 | Wells Fargo | Maintains | Overweight | — |
| 31 Mar 2025 | Evercore ISI Group | Maintains | Hold | — |
| 28 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Dec 2024 | Wells Fargo | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SVRA.
This page is one stock. Monday covers all of them.
SVRA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SVRA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Savara, Inc. returned −9.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SVRA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 10.0×
- EV / EBITDA
- —
Cheaper than 7% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −151.0%
- Return on assets
- −65.7%
- Dividend yield
- —
Higher than 9% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Savara, Inc. has a market value of $939.9M and an enterprise value of $1.0B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$139.3M.
Free cash flow in the twelve months to 30 June 2026: −$110.7M.
Savara, Inc. spent $5.1M on share buybacks in the twelve months to 30 June 2026.
Savara, Inc. employs 70 people.
Data provided by Twelve Data
SVRA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SVRA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Savara, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SVRA
What is the SVRA stock price forecast for 2026-2027?
The 9 Wall Street analysts covering Savara, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SVRA stock a buy right now?
Of the 9 analysts covering Savara, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Savara, Inc. 28 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SVRA?
As at 21 Nov 2026, Savara, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (75 of 100).
Will SVRA stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts implies +147.1% from the last close, and Ticker Nerd's factor model ranks Savara, Inc. 28 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SVRA stock forecast for 2030?
No analyst covering Savara, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SVRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $16 over the next 12 months.
How has SVRA stock performed over the past year?
Savara, Inc. returned -9.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Savara, Inc. do?
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company’s work centers on developing inhaled therapies designed to address serious lung disorders with limited treatment options, with a particular emphasis on autoimmune pulmonary alveolar proteinosis.
About Savara, Inc.
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company’s work centers on developing inhaled therapies designed to address serious lung disorders with limited treatment options, with a particular emphasis on autoimmune pulmonary alveolar proteinosis. Its lead product candidate, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor being advanced through late-stage clinical development. Savara’s current business is concentrated on research, clinical development, and regulatory progress in orphan and specialty respiratory medicine, rather than on a broad commercial product portfolio. The company serves a niche market within biotechnology and pharmaceuticals, where expertise in pulmonary medicine and rare disease development is central to its role.
CEO Mr. Matthew Pauls J.D., M.B.A. · 70 employees · United States · https://www.savarapharma.com